Stealth Lipid-Free LNPs: A New Technology that Offers Colloidal Stability and in vivo Potency, While Sidestepping PEG-Related Liabilities
- Eliminating the need for PEG-lipids by using sodium triphosphate (3P) to achieve colloidal stability, reducing risks of hypersensitivity, anti-PEG antibodies, and accelerated blood clearance
- Preserving essential particle characteristics, such as size, morphology, and polydispersity, while modifying surface charge through 3P binding
- Delivering targeted liver expression with minimal off-target activity and outperforms PEG-LNPs in photon flux six hours post-dose in vivo
- Demonstrating strong tolerability in mice, supporting the use of 3P-LNPs as a viable PEG-free vector for vaccines and the potential to enable chronic intravenous gene replacement therapies